{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T14:56:33Z","timestamp":1789397793094,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82072753"],"award-info":[{"award-number":["82072753"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Wuhan University \u201cClinical medicine +X\u201d youth top project","award":["413000621"],"award-info":[{"award-number":["413000621"]}]},{"name":"Wuhan University Zhongnan Hospital medical science and technology innovation platform construction support project","award":["PTXM2024008"],"award-info":[{"award-number":["PTXM2024008"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s11010-025-05319-7","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T11:15:30Z","timestamp":1749640530000},"page":"5429-5446","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["TAP1 promotes immune escape by activating JNK\/STAT1\/PD-L1 signaling in EBV-associated gastric cancer"],"prefix":"10.1007","volume":"480","author":[{"given":"Wenqing","family":"Shan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqingyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranran","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoran","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,11]]},"reference":[{"key":"5319_CR1","doi-asserted-by":"publisher","first-page":"103841","DOI":"10.1016\/j.critrevonc.2022.103841","volume":"181","author":"MJ L\u00f3pez","year":"2023","unstructured":"L\u00f3pez MJ, Carbajal J, Alfaro AL, Saravia LG, Zanabria D, Araujo JM et al (2023) Characteristics of gastric cancer around the world. Crit Rev Oncol Hematol 181:103841","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"5319_CR2","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12964-022-00854-y","volume":"20","author":"A Naimi","year":"2022","unstructured":"Naimi A, Mohammed RN, Raji A, Chupradit S, Yumashev AV, Suksatan W et al (2022) Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Commun Signal 20(1):44","journal-title":"Cell Commun Signal"},{"issue":"2","key":"5319_CR3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41571-021-00564-3","volume":"19","author":"FG Dall\u2019Olio","year":"2022","unstructured":"Dall\u2019Olio FG, Marabelle A, Caramella C, Garcia C, Aldea M, Chaput N et al (2022) Tumour burden and efficacy of immune-checkpoint inhibitors. Nat Rev Clin Oncol 19(2):75\u201390","journal-title":"Nat Rev Clin Oncol"},{"key":"5319_CR4","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi S, Yuan R, Engleman EG (2021) Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 16:223\u2013249","journal-title":"Annu Rev Pathol."},{"issue":"1","key":"5319_CR5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41467-022-35431-x","volume":"14","author":"S Li","year":"2023","unstructured":"Li S, Yu W, Xie F, Luo H, Liu Z, Lv W et al (2023) Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer. Nat Commun 14(1):8","journal-title":"Nat Commun"},{"issue":"2","key":"5319_CR6","doi-asserted-by":"publisher","first-page":"188615","DOI":"10.1016\/j.bbcan.2021.188615","volume":"1876","author":"K Li","year":"2021","unstructured":"Li K, Zhang A, Li X, Zhang H, Zhao L (2021) Advances in clinical immunotherapy for gastric cancer. Biochim Biophys Acta Rev Cancer 1876(2):188615","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"8","key":"5319_CR7","doi-asserted-by":"publisher","first-page":"e002467","DOI":"10.1136\/jitc-2021-002467","volume":"9","author":"D Zeng","year":"2021","unstructured":"Zeng D, Wu J, Luo H, Li Y, Xiao J, Peng J et al (2021) Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer. J Immunother Cancer. 9(8):e002467","journal-title":"J Immunother Cancer."},{"key":"5319_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ctrv.2018.03.006","volume":"66","author":"M Naseem","year":"2018","unstructured":"Naseem M, Barzi A, Brezden-Masley C, Puccini A, Berger MD, Tokunaga R et al (2018) Outlooks on Epstein-Barr virus associated gastric cancer. Cancer Treat Rev 66:15\u201322","journal-title":"Cancer Treat Rev"},{"key":"5319_CR9","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.canlet.2020.09.019","volume":"495","author":"J Yang","year":"2020","unstructured":"Yang J, Liu Z, Zeng B, Hu G, Gan R (2020) Epstein-Barr virus-associated gastric cancer: a distinct subtype. Cancer Lett 495:191\u2013199","journal-title":"Cancer Lett"},{"key":"5319_CR10","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jcv.2018.03.001","volume":"102","author":"SK Dunmire","year":"2018","unstructured":"Dunmire SK, Verghese PS, Balfour HH Jr (2018) Primary Epstein-Barr virus infection. J Clin Virol 102:84\u201392","journal-title":"J Clin Virol"},{"issue":"20","key":"5319_CR11","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1016\/j.cell.2022.08.026","volume":"185","author":"B Damania","year":"2022","unstructured":"Damania B, Kenney SC, Raab-Traub N (2022) Epstein-Barr virus: biology and clinical disease. Cell. 185(20):3652\u20133670","journal-title":"Cell."},{"key":"5319_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1146\/annurev-pathmechdis-012418-013023","volume":"14","author":"PJ Farrell","year":"2019","unstructured":"Farrell PJ (2019) Epstein-Barr virus and cancer. Annu Rev Pathol. 14:29\u201353","journal-title":"Annu Rev Pathol."},{"issue":"7","key":"5319_CR13","doi-asserted-by":"publisher","first-page":"3813","DOI":"10.1182\/blood-2007-03-080309","volume":"111","author":"I Guasparri","year":"2008","unstructured":"Guasparri I, Bubman D, Cesarman E (2008) EBV LMP2A affects LMP1-mediated NF-kappaB signaling and survival of lymphoma cells by regulating TRAF2 expression. Blood. 111(7):3813\u201320","journal-title":"Blood."},{"key":"5319_CR14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.virol.2019.06.006","volume":"534","author":"J Wang","year":"2019","unstructured":"Wang J, Liu W, Zhang X, Zhang Y, Xiao H, Luo B (2019) LMP2A induces DNA methylation and expression repression of AQP3 in EBV-associated gastric carcinoma. Virology 534:87\u201395","journal-title":"Virology"},{"issue":"10","key":"5319_CR15","doi-asserted-by":"publisher","first-page":"e49689","DOI":"10.15252\/embr.201949689","volume":"21","author":"LP Gong","year":"2020","unstructured":"Gong LP, Chen JN, Dong M, Xiao ZD, Feng ZY, Pan YH et al (2020) Epstein-Barr virus-derived circular RNA LMP2A induces stemness in EBV-associated gastric cancer. EMBO Rep 21(10):e49689","journal-title":"EMBO Rep"},{"issue":"7681","key":"5319_CR16","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nature24627","volume":"551","author":"A Blees","year":"2017","unstructured":"Blees A, Januliene D, Hofmann T, Koller N, Schmidt C, Trowitzsch S et al (2017) Structure of the human MHC-I peptide-loading complex. Nature 551(7681):525\u2013528","journal-title":"Nature"},{"issue":"23","key":"5319_CR17","doi-asserted-by":"publisher","first-page":"e2320879121","DOI":"10.1073\/pnas.2320879121","volume":"121","author":"J Lee","year":"2024","unstructured":"Lee J, Oldham ML, Manon V, Chen J (2024) Principles of peptide selection by the transporter associated with antigen processing. Proc Natl Acad Sci USA 121(23):e2320879121","journal-title":"Proc Natl Acad Sci USA"},{"key":"5319_CR18","doi-asserted-by":"publisher","first-page":"5072","DOI":"10.1016\/j.csbj.2021.09.006","volume":"19","author":"M Padariya","year":"2021","unstructured":"Padariya M, Kote S, Mayordomo M, Dapic I, Alfaro J, Hupp T et al (2021) Structural determinants of peptide-dependent TAP1-TAP2 transit passage targeted by viral proteins and altered by cancer-associated mutations. Comput Struct Biotechnol J 19:5072\u20135091","journal-title":"Comput Struct Biotechnol J"},{"issue":"1","key":"5319_CR19","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s43018-021-00280-y","volume":"3","author":"M Shen","year":"2022","unstructured":"Shen M, Smith HA, Wei Y, Jiang YZ, Zhao S, Wang N et al (2022) Pharmacological disruption of the MTDH-SND1 complex enhances tumor antigen presentation and synergizes with anti-PD-1 therapy in metastatic breast cancer. Nat Cancer 3(1):60\u201374","journal-title":"Nat Cancer"},{"key":"5319_CR20","doi-asserted-by":"publisher","first-page":"1013790","DOI":"10.3389\/fonc.2022.1013790","volume":"12","author":"ZD Wang","year":"2022","unstructured":"Wang ZD, Tian X, Wang Y, Wang JJ, Ye SQ, Huang YQ et al (2022) The expression and prognostic value of transporter 1, ATP binding cassette subfamily B member in clear cell renal cell cancer with experimental validation. Front Oncol 12:1013790","journal-title":"Front Oncol"},{"issue":"13","key":"5319_CR21","doi-asserted-by":"publisher","first-page":"7168","DOI":"10.3390\/ijms23137168","volume":"23","author":"B Li","year":"2022","unstructured":"Li B, Feng Y, Hou Q, Fu Y, Luo Y (2022) Antigen peptide transporter 1 (TAP1) promotes resistance to MEK inhibitors in pancreatic cancers. Int J Mol Sci. 23(13):7168","journal-title":"Int J Mol Sci."},{"issue":"1","key":"5319_CR22","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1038\/s41467-019-11728-2","volume":"10","author":"G Garrido","year":"2019","unstructured":"Garrido G, Schrand B, Rabasa A, Levay A, D\u2019Eramo F, Berezhnoy A et al (2019) Tumor-targeted silencing of the peptide transporter TAP induces potent antitumor immunity. Nat Commun 10(1):3773","journal-title":"Nat Commun"},{"issue":"1","key":"5319_CR23","doi-asserted-by":"publisher","first-page":"367","DOI":"10.7314\/APJCP.2013.14.1.367","volume":"14","author":"Y Ding","year":"2013","unstructured":"Ding Y, Li XR, Yang KY, Huang LH, Hu G, Gao K (2013) Proteomics analysis of gastric epithelial AGS cells infected with Epstein-Barr virus. Asian Pac J Cancer Prev 14(1):367\u2013372","journal-title":"Asian Pac J Cancer Prev"},{"issue":"Pt 3","key":"5319_CR24","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1099\/vir.0.045237-0","volume":"94","author":"DN Kim","year":"2013","unstructured":"Kim DN, Seo MK, Choi H, Kim SY, Shin HJ, Yoon AR et al (2013) Characterization of naturally Epstein-Barr virus-infected gastric carcinoma cell line YCCEL1. J Gen Virol 94(Pt 3):497\u2013506","journal-title":"J Gen Virol"},{"issue":"1","key":"5319_CR25","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41392-023-01471-y","volume":"8","author":"L Sun","year":"2023","unstructured":"Sun L, Su Y, Jiao A, Wang X, Zhang B (2023) T cells in health and disease. Signal Transduct Target Ther 8(1):235","journal-title":"Signal Transduct Target Ther"},{"issue":"17","key":"5319_CR26","doi-asserted-by":"publisher","first-page":"6326","DOI":"10.1074\/jbc.M117.819201","volume":"293","author":"T Matsumura","year":"2018","unstructured":"Matsumura T, Hida S, Kitazawa M, Fujii C, Kobayashi A, Takeoka M et al (2018) Fascin1 suppresses RIG-I-like receptor signaling and interferon-\u03b2 production by associating with I\u03baB kinase \u03f5 (IKK\u03f5) in colon cancer. J Biol Chem 293(17):6326\u20136336","journal-title":"J Biol Chem"},{"issue":"6","key":"5319_CR27","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.7150\/thno.80555","volume":"13","author":"X Li","year":"2023","unstructured":"Li X, Chen X, Gong S, Zhao J, Yao C, Zhu H et al (2023) Platelets promote CRC by activating the C5a\/C5aR1 axis via PSGL-1\/JNK\/STAT1 signaling in tumor-associated macrophages. Theranostics 13(6):2040\u20132056","journal-title":"Theranostics"},{"issue":"1","key":"5319_CR28","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41392-020-00312-6","volume":"5","author":"H Yu","year":"2020","unstructured":"Yu H, Lin L, Zhang Z, Zhang H, Hu H (2020) Targeting NF-\u03baB pathway for the therapy of diseases: mechanism and clinical study. Signal Transduct Target Ther 5(1):209","journal-title":"Signal Transduct Target Ther"},{"key":"5319_CR29","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3389\/fonc.2018.00265","volume":"8","author":"A El-Sharkawy","year":"2018","unstructured":"El-Sharkawy A, Al Zaidan L, Malki A (2018) Epstein-Barr virus-associated malignancies: roles of viral oncoproteins in carcinogenesis. Front Oncol 8:265","journal-title":"Front Oncol"},{"issue":"5","key":"5319_CR30","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1002\/jmv.25381","volume":"91","author":"R Incrocci","year":"2019","unstructured":"Incrocci R, McAloon J, Montesano M, Bardahl J, Vagvala S, Stone A et al (2019) Epstein-Barr virus LMP2A utilizes Syk and PI3K to activate NF-\u03baB in B-cell lymphomas to increase MIP-1\u03b1 production. J Med Virol 91(5):845\u2013855","journal-title":"J Med Virol"},{"issue":"1","key":"5319_CR31","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","volume":"21","author":"M Yi","year":"2022","unstructured":"Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K (2022) Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions. Mol Cancer 21(1):28","journal-title":"Mol Cancer"},{"issue":"11","key":"5319_CR32","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1038\/s41419-020-03140-2","volume":"11","author":"Q Gou","year":"2020","unstructured":"Gou Q, Dong C, Xu H, Khan B, Jin J, Liu Q et al (2020) PD-L1 degradation pathway and immunotherapy for cancer. Cell Death Dis 11(11):955","journal-title":"Cell Death Dis"},{"issue":"1","key":"5319_CR33","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3390\/cancers14010031","volume":"14","author":"C Heawchaiyaphum","year":"2021","unstructured":"Heawchaiyaphum C, Pientong C, Yoshiyama H, Iizasa H, Panthong W, Ekalaksananan T (2021) General features and novel gene signatures that identify Epstein-Barr virus-associated epithelial cancers. Cancers (Basel). 14(1):31","journal-title":"Cancers (Basel)."},{"issue":"1","key":"5319_CR34","doi-asserted-by":"publisher","first-page":"3108","DOI":"10.1038\/s41467-019-10902-w","volume":"10","author":"S Hong","year":"2019","unstructured":"Hong S, Liu D, Luo S, Fang W, Zhan J, Fu S et al (2019) The genomic landscape of Epstein-Barr virus-associated pulmonary lymphoepithelioma-like carcinoma. Nat Commun 10(1):3108","journal-title":"Nat Commun"},{"issue":"11","key":"5319_CR35","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/s41419-019-2060-9","volume":"10","author":"S Mai","year":"2019","unstructured":"Mai S, Xiao R, Shi L, Zhou X, Yang T, Zhang M et al (2019) MicroRNA-18a promotes cancer progression through SMG1 suppression and mTOR pathway activation in nasopharyngeal carcinoma. Cell Death Dis 10(11):819","journal-title":"Cell Death Dis"},{"key":"5319_CR36","doi-asserted-by":"publisher","first-page":"584626","DOI":"10.3389\/fimmu.2020.584626","volume":"11","author":"F Antonangeli","year":"2020","unstructured":"Antonangeli F, Natalini A, Garassino MC, Sica A, Santoni A, Di Rosa F (2020) Regulation of PD-L1 expression by NF-\u03baB in cancer. Front Immunol. 11:584626","journal-title":"Front Immunol."},{"issue":"6","key":"5319_CR37","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1002\/hep.32071","volume":"74","author":"S Ghosh","year":"2021","unstructured":"Ghosh S, Devereaux MW, Anderson AL, Gehrke S, Reisz JA, D\u2019Alessandro A et al (2021) NF-\u03baB regulation of LRH-1 and ABCG5\/8 potentiates phytosterol role in the pathogenesis of parenteral nutrition-associated cholestasis. Hepatology 74(6):3284\u20133300","journal-title":"Hepatology"},{"issue":"1","key":"5319_CR38","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s13046-018-0953-6","volume":"37","author":"C Lin","year":"2018","unstructured":"Lin C, Zong J, Lin W, Wang M, Xu Y, Zhou R et al (2018) EBV-miR-BART8-3p induces epithelial-mesenchymal transition and promotes metastasis of nasopharyngeal carcinoma cells through activating NF-\u03baB and Erk1\/2 pathways. J Exp Clin Cancer Res 37(1):283","journal-title":"J Exp Clin Cancer Res"},{"issue":"19","key":"5319_CR39","doi-asserted-by":"publisher","first-page":"5074","DOI":"10.1158\/0008-5472.CAN-20-4321","volume":"81","author":"J Ge","year":"2021","unstructured":"Ge J, Wang J, Xiong F, Jiang X, Zhu K, Wang Y et al (2021) Epstein-Barr virus-encoded circular RNA CircBART2.2 promotes immune escape of nasopharyngeal carcinoma by regulating PD-L1. Cancer Res. 81(19):5074\u20135088","journal-title":"Cancer Res."},{"issue":"6","key":"5319_CR40","doi-asserted-by":"publisher","first-page":"189218","DOI":"10.1016\/j.bbcan.2024.189218","volume":"1879","author":"M Alsaadawe","year":"2024","unstructured":"Alsaadawe M, Radman BA, Long J, Alsaadawi M, Fang W, Lyu X (2024) Epstein Barr virus: a cellular hijacker in cancer. Biochim Biophys Acta Rev Cancer 1879(6):189218","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"5319_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virol.2019.03.019","volume":"532","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Liu W, Zhang W, Wang W, Song Y, Xiao H et al (2019) Constitutive activation of the canonical NF-\u03baB signaling pathway in EBV-associated gastric carcinoma. Virology 532:1\u201310","journal-title":"Virology"},{"issue":"2","key":"5319_CR42","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/s11262-023-01970-8","volume":"59","author":"Y Liang","year":"2023","unstructured":"Liang Y, Liu W, Zhao M, Shi D, Zhang Y, Luo B (2023) Nuclear respiratory factor 1 promotes the progression of EBV-associated gastric cancer and maintains EBV latent infection. Virus Genes 59(2):204\u2013214","journal-title":"Virus Genes"},{"issue":"6","key":"5319_CR43","doi-asserted-by":"publisher","first-page":"e1004906","DOI":"10.1371\/journal.ppat.1004906","volume":"11","author":"C Rancan","year":"2015","unstructured":"Rancan C, Schirrmann L, H\u00fcls C, Zeidler R, Moosmann A (2015) Latent membrane protein LMP2A impairs recognition of EBV-infected cells by CD8+ T cells. PLoS Pathog. 11(6):e1004906","journal-title":"PLoS Pathog."},{"issue":"2","key":"5319_CR44","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s43440-021-00238-y","volume":"73","author":"KS Abdelrahman","year":"2021","unstructured":"Abdelrahman KS, Hassan HA, Abdel-Aziz SA, Marzouk AA, Narumi A, Konno H et al (2021) JNK signaling as a target for anticancer therapy. Pharmacol Rep 73(2):405\u2013434","journal-title":"Pharmacol Rep"},{"issue":"3","key":"5319_CR45","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.3390\/ijms23031108","volume":"23","author":"LJW Pua","year":"2022","unstructured":"Pua LJW, Mai CW, Chung FF, Khoo AS, Leong CO, Lim WM et al (2022) Functional roles of JNK and p38 MAPK signaling in nasopharyngeal carcinoma. Int J Mol Sci. 23(3):1108","journal-title":"Int J Mol Sci."},{"issue":"9","key":"5319_CR46","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.3390\/cancers13092196","volume":"13","author":"SY Tam","year":"2021","unstructured":"Tam SY, Law HK (2021) JNK in tumor microenvironment: present findings and challenges in clinical translation. Cancers (Basel). 13(9):2196","journal-title":"Cancers (Basel)."},{"issue":"5","key":"5319_CR47","doi-asserted-by":"publisher","first-page":"E131","DOI":"10.1038\/ncb0502-e131","volume":"4","author":"E Shaulian","year":"2002","unstructured":"Shaulian E (2002) Karin M AP-1 as a regulator of cell life and death. Nat Cell Biol 4(5):E131\u2013E136","journal-title":"Nat Cell Biol"},{"issue":"4","key":"5319_CR48","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.3390\/jcm12041336","volume":"12","author":"Y Sato","year":"2023","unstructured":"Sato Y, Okamoto K, Kida Y, Mitsui Y, Kawano Y, Sogabe M et al (2023) Overview of chemotherapy for gastric cancer. J Clin Med. 12(4):1336","journal-title":"J Clin Med."},{"key":"5319_CR49","doi-asserted-by":"publisher","first-page":"175628481986976","DOI":"10.1177\/1756284819869767","volume":"12","author":"G Brar","year":"2019","unstructured":"Brar G, Shah MA (2019) The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma. Therap Adv Gastroenterol 12:1756284819869767","journal-title":"Therap Adv Gastroenterol"},{"issue":"2","key":"5319_CR50","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"YK Kang","year":"2022","unstructured":"Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, Chung HC et al (2022) Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 23(2):234\u2013247","journal-title":"Lancet Oncol"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-025-05319-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-025-05319-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-025-05319-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:02:28Z","timestamp":1760173348000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-025-05319-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,11]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["5319"],"URL":"https:\/\/doi.org\/10.1007\/s11010-025-05319-7","relation":{},"ISSN":["0300-8177","1573-4919"],"issn-type":[{"value":"0300-8177","type":"print"},{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,11]]},"assertion":[{"value":"7 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"The studies were conducted in accordance with the Ethics Committee of Zhongnan Hospital of Wuhan University. All experimental protocols and procedures involving animals were reviewed and approved by the Ethics Committee for Experimental Animals of the Zhongnan Hospital, Wuhan University (approval number: WP20220343). All human pathological tissue specimens used in this study were obtained from Zhongnan Hospital of Wuhan University. The collection of these specimens was approved by the Ethics Committee of the Zhongnan Hospital of Wuhan University, and informed consent was obtained from all patients (approval number: ZN2024386).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All the authors agree to publish this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}